X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (53) 53
index medicus (51) 51
humans (50) 50
male (40) 40
female (38) 38
middle aged (35) 35
aged (34) 34
adult (29) 29
chemotherapy (21) 21
cancer (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
treatment outcome (14) 14
aged, 80 and over (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
prognosis (10) 10
fluorouracil (9) 9
fluorouracil - administration & dosage (9) 9
lung neoplasms - drug therapy (9) 9
metastasis (9) 9
oxaliplatin (9) 9
research (9) 9
breast-cancer (8) 8
deoxycytidine - analogs & derivatives (8) 8
neoplasm staging (8) 8
quality of life (8) 8
therapy (8) 8
antineoplastic agents - therapeutic use (7) 7
carcinoma (7) 7
care and treatment (7) 7
cetuximab (7) 7
colorectal cancer (7) 7
colorectal neoplasms - drug therapy (7) 7
deoxycytidine - administration & dosage (7) 7
neoplasm metastasis (7) 7
carcinoma, non-small-cell lung - drug therapy (6) 6
italy (6) 6
organoplatinum compounds - administration & dosage (6) 6
tumors (6) 6
adolescent (5) 5
analysis (5) 5
cisplatin - administration & dosage (5) 5
clinical trials (5) 5
colorectal neoplasms - pathology (5) 5
colorectal-cancer (5) 5
disease-free survival (5) 5
expression (5) 5
follow-up studies (5) 5
gemcitabine (5) 5
leucovorin (5) 5
lung neoplasms - secondary (5) 5
medicine (5) 5
metaanalysis (5) 5
surgery (5) 5
survival (5) 5
young adult (5) 5
abridged index medicus (4) 4
adenocarcinoma (4) 4
bevacizumab (4) 4
camptothecin - analogs & derivatives (4) 4
carcinoma, non-small-cell lung - pathology (4) 4
case-control studies (4) 4
cisplatin (4) 4
clinical-trials (4) 4
diagnosis (4) 4
disease progression (4) 4
docetaxel (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
enzyme-linked immunosorbent assay (4) 4
health aspects (4) 4
hematology, oncology and palliative medicine (4) 4
immunohistochemistry (4) 4
infusions, intravenous (4) 4
irinotecan (4) 4
kaplan-meier estimate (4) 4
liver neoplasms - secondary (4) 4
lung neoplasms - pathology (4) 4
lymphatic metastasis (4) 4
lymphocytes (4) 4
medicine, research & experimental (4) 4
metastases (4) 4
multicenter (4) 4
multidisciplinary sciences (4) 4
neoplasms - drug therapy (4) 4
pancreatic cancer (4) 4
pancreatic carcinoma (4) 4
pancreatic neoplasms - drug therapy (4) 4
pancreatic neoplasms - pathology (4) 4
patients (4) 4
pilot projects (4) 4
randomized-trial (4) 4
risk factors (4) 4
survival rate (4) 4
trial (4) 4
usage (4) 4
5-fluorouracil (3) 3
adenocarcinoma - drug therapy (3) 3
age (3) 3
angiogenesis (3) 3
antibodies, monoclonal - adverse effects (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 11/2017, Volume 141, Issue 9, pp. 1803 - 1810
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, pp. e0169174 - e0169174
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 4, pp. 574 - 581
The combination of gemcitabine and oxaliplatin with panitumumab versus gemcitabine and oxaliplatin alone has been evaluated in a phase 2, randomized trial as a... 
KRAS | panitumumab | biliary cancer | chemotherapy | cholangiocarcinoma | gemcitabine and oxaliplatin (GEMOX) | GROWTH-FACTOR-RECEPTOR | GALLBLADDER CANCER | OPEN-LABEL | II TRIAL | CAPECITABINE | ADVANCED CHOLANGIOCARCINOMA | CETUXIMAB | THERAPY | ONCOLOGY | Adenocarcinoma - pathology | Prognosis | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Male | Organoplatinum Compounds - administration & dosage | Adult | Female | Adenocarcinoma - genetics | Bile Duct Neoplasms - genetics | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Bile Ducts, Intrahepatic - pathology | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Treatment Outcome | Adenocarcinoma - drug therapy | Disease-Free Survival | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cholangiocarcinoma - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Bile Ducts, Extrahepatic - pathology | Gallbladder Neoplasms - pathology | Bile Duct Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Clinical trials | Usage | Dosage and administration | Gemcitabine | Index Medicus | Abridged Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2017, Volume 141, Issue 9, pp. 1803 - 1810
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2019, Volume 19, Issue 1, pp. 283 - 283
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4501 - 4507
Journal Article
Oncology, ISSN 0030-2414, 04/2015, Volume 88, Issue 5, pp. 273 - 280
Objectives: Patients with metastatic renal cell carcinoma (mRCC) received sunitinib in a global expanded-access program (EAP). Here, we report the efficacy and... 
Clinical Study | Sunitinib malate | Receptor tyrosine kinase inhibitor | Safety | Renal cell carcinoma | Expanded-access program | Survival | MULTICENTER | GUIDELINES | SU11248 | BREAST-CANCER | INTERFERON-ALPHA | ONCOLOGY | CLINICAL-TRIALS | IN-VIVO | TYROSINE KINASE INHIBITOR | ELDERLY-PATIENTS | ENDOTHELIAL GROWTH-FACTOR | Follow-Up Studies | Compassionate Use Trials | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Indoles - administration & dosage | Incidence | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Hypertension - chemically induced | Leukopenia - chemically induced | Pyrroles - adverse effects | Adult | Female | Carcinoma, Renal Cell - drug therapy | Neutropenia - chemically induced | Pyrroles - therapeutic use | Drug Administration Schedule | Kaplan-Meier Estimate | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Asthenia - chemically induced | Disease-Free Survival | Indoles - adverse effects | Carcinoma, Renal Cell - secondary | Stomatitis - chemically induced | Indoles - therapeutic use | Italy | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Dysgeusia - chemically induced | Patient safety | Chemotherapy | Inhibitor drugs | Metastasis | Clinical outcomes | Kidney cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 67, pp. 32795 - 32809
Thymic stromal lymphopoietin (TSLP) has emerged as an important, but contradictory, player conditioning tumor growth. In certain contexts, by driving T helper... 
Thymic stromal lymphopoietin | Dendritic cells | OX40L | Pancreatic ductal adenocarcinoma | T helper 2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15, pp. 1478 - 1485
PurposeGiven the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous... 
SURVIVAL | LEUCOVORIN | THERAPY | ONCOLOGY | COLORECTAL-CANCER | PHASE-III | OXALIPLATIN | FLUOROURACIL | LEVAMISOLE
Journal Article
International Journal of Psychoanalysis, ISSN 0020-7578, 11/2010, Volume 101, Issue 11, pp. 2448 - 2454
Journal Article